Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 1 of about 1   

Articles published

NVO 55.63 +0.61 (1.11%)
price chart
Post-Market News: AIG, UPS, GE, GS, SBUX, BAC, CAT, YHOO, OZM, CMG, KR
Danish drug maker Novo Nordisk A/S (ADR) (NYSE:NVO) (CPH:NOVO-B) said its long-acting insulin Tresiba has been recommended for approval by advisory panel to the European Medicines Agency.